Your search for non small cell lung cancer returned 125 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Older than 2 years remove
Drugs in the Pipeline remove

Your search for non small cell lung cancer returned 125 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Cemiplimab Granted Priority Review for Advanced NSCLC

Topline results from the trial showed that compared with chemotherapy, treatment with cemiplimab-rwlc reduced the risk of death by 32% in the overall trial population.
Drugs in the Pipeline

Tepotinib Gets Priority Review for Metastatic NSCLC With METex14 Skipping Mutation

The Food and Drug Administration (FDA) has granted Priority Review to tepotinib (EMD Serono) for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 (METex14) skipping, as detected by an FDA-approved test. The application is supported by data from the ongoing,…
Drugs in the Pipeline

Mobocertinib Gets Breakthrough Status for NSCLC With EGFR Exon 20 Insertion Mutations

The FDA has granted Breakthrough Therapy designation to mobocertinib (TAK-788; Takeda) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Drugs in the Pipeline

Cemiplimab NSCLC Trial Stopped Early After Demonstrating Survival Benefit

Sanofi and Regeneron announced that the phase 3 trial evaluating cemiplimab (Libtayo®) as a potential first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer was stopped early due to “highly significant improvement” in overall survival.
Drugs in the Pipeline

Novel Bispecific Antibody Gets Breakthrough Therapy Status for NSCLC

The FDA has granted Breakthrough Therapy designation to JNJ-6372 (Janssen) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
Drugs in the Pipeline

Atezolizumab Monotherapy Under Review for First-line Treatment of Advanced NSCLC

The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for atezolizumab (Tecentriq®; Genentech) as a first-line monotherapy in patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing.